Comparison of budesonide and dexamethasone for local treatment of oral chronic graft-versus-host disease

American Journal of Health-System Pharmacy

Volumn 70, Issue 16, 2013, Pages 1383-1391

  Park, Ae Ryoung ^a   La, Hyen Oh ^a,b   Cho, Byung Sik ^b   Kim, Soon Joo ^a   Lee, Byung Koo ^c   Rhie, Jeong Yeon ^c   Gwak, Hye Sun ^c  

^a The Catholic University of Korea   (South Korea)

^b The Catholic University of Korea   (South Korea)

^c Ewha Womans University   (South Korea)

Author keywords

[No Author keywords available]

Indexed keywords

BUDESONIDE; DEXAMETHASONE; FLUCONAZOLE; ITRACONAZOLE; IMMUNOSUPPRESSIVE AGENT; MOUTHWASH;

ADULT; ALLOGENEIC STEM CELL TRANSPLANTATION; ARTICLE; ASTRINGENCY; BITTER TASTE; CHRONIC GRAFT VERSUS HOST DISEASE; CORTICOSTEROID THERAPY; DISEASE SEVERITY; DRUG WITHDRAWAL; FEMALE; FOLLOW UP; HUMAN; LOCAL THERAPY; MAJOR CLINICAL STUDY; MALE; MOUTH DISEASE; MOUTH PAIN; NATIONAL HEALTH ORGANIZATION; PROSPECTIVE STUDY; STAGING; THRUSH; TOPICAL TREATMENT; TREATMENT RESPONSE; XEROSTOMIA; CHRONIC DISEASE; COMPARATIVE STUDY; COMPLICATION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; GRAFT VS HOST DISEASE; MEDICATION COMPLIANCE; MIDDLE AGED; MOUTH DISEASES;

BUDESONIDE; CHRONIC DISEASE; DEXAMETHASONE; FEMALE; GRAFT VS HOST DISEASE; HUMANS; IMMUNOSUPPRESSIVE AGENTS; MALE; MEDICATION ADHERENCE; MIDDLE AGED; MOUTH DISEASES; MOUTHWASHES;

EID: 84895880040     PISSN: 10792082     EISSN: 15352900     Source Type: Journal    
DOI: 10.2146/ajhp120567     Document Type: Article

References (48)

1. Akpek G, Zahurak ML, Piantadosi S et al. Development of a prognostic model for grading chronic graft-versus-host disease. Blood. 2001; 97:1219-26.
2. Lee SJ, Klein JP, Barrett AJ et al. Severity of chronic graft-versus-host disease: association with treatment-related mortality and relapse. Blood. 2002; 100:406-14.
3. Baird K, Pavletic SZ. Chronic graft versus host disease. Curr Opin Hematol. 2006; 13:426-35.
4. Akpek G. Titrating graft-versus-host disease: is it worth a try? Bone Marrow Transplant. 2006; 38:653-6.
5. Perez-Simon JA, Sanchez-Abarca I, Diez-Campelo M et al. Chronic graft-versushost disease: pathogenesis and clinical management. Drugs. 2006; 66:1041-57.
6. Rocha V, Wagner JE Jr, Sobocinski KA et al. Graft-versus-host disease in children who have received a cord-blood or bone marrow transplant from an HLAidentical sibling. Eurocord and International Bone Marrow Transplant Registry Working Committee on Alternative Donor and Stem Cell Sources. N Engl J Med. 2000; 342:1846-54.
7. Vogelsang GB, Lee L, Bensen-Kennedy DM. Pathogenesis and treatment of graft-versus-host disease after bone marrow transplant. Annu Rev Med. 2003; 54:29-52.
8. Lee SJ, Vogelsang G, Flowers ME. Chronic graft-versus-host disease. Biol Blood Marrow Transplant. 2003; 9:215-33.
9. Parker P, Chao N, Nademanee A et al. Thalidomide as salvage therapy for chronic graft-versus-host disease. Blood. 1995; 86:3604-9.
10. Ratanatharathorn V, Ayash L, Lazarus HM et al. Chronic graft-versus-host disease: clinical manifestation and therapy. Bone Marrow Transplant. 2001; 28:121-9.
11. Horn TD, Rest EB, Mirenski Y et al. The significance of oral mucosal and salivary gland pathology after allogenic bone marrow transplantation. Arch Dermatol. 1995; 131:964-5.
12. Nagler RM, Nagler A. Major salivary gland involvement in graft-vs.-host disease: considerations related to pathogenesis, the role of cytokines and therapy. Cytokines Cell Mol Ther. 1999; 5:227-32.
13. Jacobsohn DA, Margolis J, Doherty J et al. Weight loss and malnutrition in patients with chronic graft-vs-host disease. Bone Marrow Transplant. 2002; 29:231-6.
14. Woo SB, Lee SJ, Schubert MM. Graft-vshost disease. Crit Rev Oral Biol Med. 1997; 8:201-16.
15. Schwinghammer TL, Bloom EJ. Pharmacologic prophylaxis of acute graft-versushost disease after allogenic marrow transplantation. Clin Pharm. 1993; 12:736-61.
16. Epstein JB, Gorsky M, Epstein MS et al. Topical azathioprine in the treatment of immune-mediated chronic oral inflammatory conditions. Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 2001; 91:56-61.
17. Epstein JB, Reece DE. Topical cyclosporine A for treatment of oral chronic graft-versus-host disease. Bone Marrow Transplant. 1994; 13:81-6.
18. Redding SW, Callander NS, Haveman CW et al. Treatment of oral chronic graftversus-host disease with PUVA therapy: case report and literature review. Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 1998; 86:183-7.
19. Elad S, Garfunkel AA, Enk CD et al. Ultraviolet B irradiation: a new therapeutic concept for the management of oral manifestations of graft-versus-host disease. Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 1999; 88:444-50.
20. Epstein J, Nantel S, Sheoltch SM. Topical azathioprine in the combined treatment of chronic oral graft-versus-host disease. Bone Marrow Transplant. 2000; 25:683-7.
21. Eckardt A, Starke O, Stadler M et al. Severe oral chronic graft-versus-host disease following allogeneic bone marrow transplantation: highly effective treatment with topical tacrolimus. Oral Oncol. 2004; 40:811-4.
22. Wolff D, Anders V, Corio R et al. Oral PUVA and topical steroids for treatment of oral manifestations of chronic graftvs.- host disease. Photodermatol Photoimmunol Photomed. 2004; 20:184-90.
23. Rutgeerts P, Lofberg R, Malchow H et al. A comparison of budesonide with prednisolone for active Crohn's disease. N Engl J Med. 1994; 331:842-5.
24. Spencer CM, McTravish D. Budesonide. A review of its pharmacological properties and therapeutic efficacy in inflammatory bowel disease. Drugs. 1995; 50:854-72.
25. Thalen A, Brattsand R, Andersson PH. Development of glucocorticoids with enhanced ratio between topical and systemic effects. Acta Derm Venereol. 1989; 69(suppl):11-9.
26. Hellers G, Cortot A, Jewell D et al. Oral budesonide for prevention of postsurgical recurrence in Crohn's disease. The IOIBD budesonide study group. Gastroenterology. 1999; 116:294-300.
27. Lofberg R, Danielsson A, Suhr O et al. Oral budesonide versus prednisolone in patients with active extensive and leftsided ulcerative colitis. Gastroenterology. 1996; 110:1713-8.
28. Sari I, Altuntas F, Kocyigit I et al. The effect of budesonide mouthwash on oral chronic graft versus host disease. Am J Hematol. 2007; 82:349-56.
29. Elad S, Or R, Garfunkel AA et al. Budesonide: a novel treatment for oral chronic graft versus host disease. Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 2003; 95:308-31.
30. Gonzalez-Moles MA, Scully C. Vesiculoerosive oral mucosal disease-management with topical corticosteroids: (1) fundamental principles and specific agents available. J Dent Res. 2005; 84:294-301.
31. Imanguli MM, Pavletic SZ, Guadagnini JP et al. Chronic graft versus host disease of oral mucosa: review of available therapies. Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 2006; 101:175-83.
32. Schubert MM, Correa ME. Oral graftversus-host disease. Dent Clin N Am. 2008; 52:79-109.
33. Filipovich AH, Weisdorf D. National Institutes of Health consensus development project on criteria for clinical trials in chronic graft-versus-host disease: I. Diagnosis and staging working group report. Biol Blood Marrow Transplant. 2005; 11:945-56.
34. Pavletic SZ, Martin P, Lee SJ et al. Measuring therapeutic response in chronic graft-versus-host disease: National Institutes of Health consensus development project on criteria for clinical trials in chronic graft-versus-host disease. IV. Response criteria working group report. Biol Blood Marrow Transplant. 2006; 12:252-66.
35. Wewers ME, Lowe NK. A critical review of visual analogue scales in the measurement of clinical phenomena. Res Nurs Health. 1990; 13:227-36.
36. Iwasaki T. Recent advances in the treatment of graft-versus-host disease. Clin Med Res. 2004; 2:243-52.
37. Sullivan K, Shulman HM, Storb R et al. Chronic graft-versus-host disease in 52 patients: adverse natural course and successful treatment with combination immunosuppression. Blood. 1981; 57:267-76.
38. Flowers ME, Parker PM Johnston LJ et al. Comparison of chronic graft-versus-host disease after transplantation of peripheral blood stem cells versus bone marrow in allogenic recipients: long-term followup of a randomized trial. Blood. 2002; 100:415-9.
39. Hogan W, Storb R. Use of cyclosporine in hematopoietic cell transplantation. Transplant Proc. 2004; 36:367-71.
40. Sullivan K, Witherspoon RP, Storb R et al. Alternating-day cyclosporine and prednisolone for treatment of high-risk chronic graft-v-host disease. Blood. 1988; 72:555-61.
41. Koc S, Leisenring W, Flowers ME et al. Therapy for chronic graft-versus-host disease: a randomized trial comparing cyclosporine plus prednisone versus prednisone alone. Blood. 2002; 100:48-51.
42. Johnston L, Brown J, Schizuru JA et al. Rapamycin (sirolimus) for treatment of chronic graft-versus-host disease. Biol Blood Marrow Transplant. 2005; 11:47-55.
43. Busca A, Locatelli F, Marmont F et al. Response to mycophenolate mofetil therapy in refractory chronic graft-versus-host disease. Haematologica. 2003; 88:837-9.
44. Couriel DR, Hosing C, Saliba R et al. Extracorporeal photochemotherapy for the treatment of steroid-resistant chronic GVHD. Blood. 2006; 107:3074-80.
45. Gilman A, Chan KW, Mogul A et al. Hydroxychloroquine for the treatment of chronic graft-versus-host disease. Biol Blood Marrow Transplant. 2000; 6:327-34.
46. Lee S, Wegner SA, McGarigle CJ et al. Treatment of chronic graft-versus-host disease with clofazimine. Blood. 1997; 89:2298-302.
47. Goldberg J, Jacobsohn DA, Margolis J et al. Pentostatin for the treatment of chronic graft-versus-host disease in children. J Pediatr Hematol Oncol. 2003; 25:584-8.
48. Giaccone L, Martin P, Carpenter P et al. Safety and potential efficacy of low-dose methotrexate for treatment of chronic graft-versus-host disease. Bone Marrow Transplant. 2005; 36:337-41.